25th Annual International Lung Cancer Congress®

Welcome, Introductions, and Presession Survey

EGFR Exon 20 Mutations: State of the Art

Classical EGFR Mutations: First-Line Therapy

Classical EGFR Mutations: Therapy After Acquired Resistance

Debate: EGFR Mutations: Is More Better in First-Line?

Panel Discussion

Breakfast & Non-CME Product Theater

Break

Updates on Radiation Techniques for Locally Advanced Disease and When to Re-Irradiate

Pushing the Envelope in Locally Advanced Disease: Surgical Techniques

Updates in Targeted Therapy for Locally Advanced NSCLC

Immunotherapy in Locally Advanced NSCLC: Latest Findings

Diagnosis and Management of Pneumonitis in Locally Advanced NSCLC

Postsession Survey

Case-Based Panel Discussion in Locally Advanced NSCLC

Q&A Session

Lunch

Non-CME Lunch Product Theater

Presession Survey

Applications for ctDNA in Metastatic Disease

Applications for ctDNA in Early-Stage Disease

Novel Liquid Biopsy Data Beyond ctDNA

Panel Discussion: Where is ctDNA Ready for Prime Time?

Role of the Surgeon in Managing Oligometastases

Role of the Radiation Oncologist in Managing Oligometastases

Medical Oncology Strategies for Treating Oligometastases

Immunotherapy in SCLC

Novel Approaches to Therapy in SCLC

Multidisciplinary Case-Based Discussion

Novel Agents in Mesothelioma

Novel Agents in Thymic Malignancies

Adjournment

Welcome Reception in the Exhibit Hall

Refining Molecular Testing in NSCLC: Who, When and How?

Molecular Testing in NSCLC in East Asia: Who, When and How?

HER2

BRAF

KRAS

Panel Discussion: Role of Combination Regimens

Introduction

Oncogene-Addicted Lung Cancer: The Next 20 Years

Innovative Approaches to Smoking Cessation

Lung Cancer: Where Will We Be in 10 Years?

First-Line Immunotherapy + Chemotherapy: Latest Updates

What's New in First-Line Immunotherapy-Immunotherapy Combinations

How Long Should We Continue First-Line Immunotherapy?

Panel Discussion: Single-Agent Immunotherapy vs Combinations: What Should Patients Get?

What to Do in Primary Resistance to Immunotherapy and Delayed Resistance

Other Immune Checkpoint Inhibitors Beyond PD-(L)1/CTLA-4

Future Immunotherapeutic Approaches, Including Cellular Therapy

Case-Based Panel Discussion

Overview on Overcoming Disparities in Cancer Care

Panel Discussion: What is Being Done at Your Center to Reduce Barriers to Clinical Trial Enrollment?

NTRK/NRG

ROS1

Get-Acquainted Reception in the Exhibit Hall

Overview of Applications for ADCs in Lung Cancer

Are Biomarkers Important for ADCs in Lung Cancer?

ADCs and Immunotherapy: Can We Achieve Synergy?

ADCs in Driver Mutation-Positive NSCLC: Do We Have a Real Signal?

ADCs in Early-Stage NSCLC: Is This a Good Fit?

Surgical Issues: Is Downstaging From Unresectable to Resectable a Goal?

Emerging Role for SBRT in Early-Stage NSCLC

Is Adjuvant TKI Use in Oncogene-Driven NSCLC Curative?

Current Status of Immunotherapy in Early-Stage NSCLC

Neoadjuvant Immunotherapy: Considerations From the Pathologist's Perspective